Neovasc Inc (NASDAQ:NVCN) (TSE:NVC)’s share price traded up 5% on Wednesday . The stock traded as high as $0.64 and last traded at $0.63. 971,101 shares changed hands during trading, a decline of 16% from the average session volume of 1,152,250 shares. The stock had previously closed at $0.60.
A number of research firms have recently commented on NVCN. ValuEngine raised Neovasc from a “hold” rating to a “buy” rating in a report on Wednesday, January 2nd. Zacks Investment Research raised Neovasc from a “hold” rating to a “buy” rating and set a $1.50 price target for the company in a report on Wednesday, November 21st.
The firm has a market capitalization of $14.84 million, a P/E ratio of -0.02 and a beta of 1.59.
An institutional investor recently bought a new position in Neovasc stock. Capital Research Global Investors acquired a new position in Neovasc Inc (NASDAQ:NVCN) (TSE:NVC) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 704,769 shares of the medical equipment provider’s stock, valued at approximately $1,917,000. Capital Research Global Investors owned approximately 3.62% of Neovasc as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 16.49% of the company’s stock.
Neovasc Company Profile (NASDAQ:NVCN)
Neovasc Inc, a specialty medical device company, develops, manufactures, and markets cardiovascular devices worldwide. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company also provides Peripatch tissue products.
Further Reading: What are no-load funds?
Receive News & Ratings for Neovasc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neovasc and related companies with MarketBeat.com's FREE daily email newsletter.